Jaknat — Tofacitinib
Tofacitinib was one of the earliest oral JAK-inhibitors to reach the autoimmune-disease market, and it remains a widely prescribed alternative for patients who've exhausted conventional and TNF-inhibitor therapy — its oral tablet format gives it the same logistical simplicity advantage as Baricitinib, making it a straightforward addition for distributors already carrying our injectable Adalimumab and Infliximab lines who want a complete oral option too.
- Approved indications: Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis
- Mechanism: Inhibits JAK1 and JAK3 enzymes, interrupting the intracellular signaling cascade that drives chronic inflammation
- Administration: Oral tablet, typically twice daily (immediate-release) or once daily (extended-release formulation)
- Distribution advantage: No cold chain, no infusion infrastructure, no self-injection training required — the simplest supply chain of any immunotherapy product in our catalogue
Key Product Facts
5 mg
Strength
14 tablets/strip
Pack Size
Tofacitinib
Active Ingredient
Rheumatology
Category
Enquire Now for Pricing
Price
Tofacitinib was one of the earliest oral JAK-inhibitors to reach the autoimmune-disease market, and it remains a widely prescribed alternative for patients who've exhausted conventional and TNF-inhibitor therapy — its oral tablet format gives it the same logistical simplicity advantage as Baricitinib, making it a straightforward addition for distributors already carrying our injectable Adalimumab and Infliximab lines who want a complete oral option too.
- Approved indications: Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis
- Mechanism: Inhibits JAK1 and JAK3 enzymes, interrupting the intracellular signaling cascade that drives chronic inflammation
- Administration: Oral tablet, typically twice daily (immediate-release) or once daily (extended-release formulation)
- Distribution advantage: No cold chain, no infusion infrastructure, no self-injection training required — the simplest supply chain of any immunotherapy product in our catalogue
- Boxed-warning class risk: Same JAK-inhibitor risk profile as Baricitinib — increased risk of serious infection, malignancy, major cardiovascular events, and thrombosis, particularly in patients over 50 with cardiovascular risk factors
- Screening requirement: Active TB and hepatitis screening mandatory before starting
- Contraindication: Pregnancy
- Monitoring: Regular blood counts, lipid panel, and liver function tests recommended throughout treatment
| Document |
Included |
| Certificate of Analysis (COA) |
Standard |
| Certificate of Origin (COO) |
Standard |
| MSDS |
Standard |
Stock status: Available on request | Quote turnaround: 24 hours
- Logistics: Standard export logistics, no cold chain required
- Coverage: Global export markets
- Cost advantage: Meaningfully lower shipping and handling cost compared to injectable biologics in the same therapeutic category
What is Tofacitinib used for?
Treats rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis.
Get Tofacitinib price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Does it need cold chain shipping?
No, it's an oral tablet stable at room temperature.
Is it safe for older patients?
Requires caution — JAK-inhibitors carry an elevated risk profile in patients over 50 with cardiovascular risk factors.
Who supplies Tofacitinib from India?
WHO-GMP certified tablet manufacturing with full export documentation.
